The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease
Abstract
Cerebral amyloid-β (Aβ) accumulation due to impaired Aβ clearance is a pivotal event in the pathogenesis of Alzheimer's disease (AD). Considerable brain-derived Aβ is cleared via transporting to the periphery. The liver is the largest organ responsible for the clearance of metabolites in the periphery. Whether the liver physiologically clears circulating Aβ and its therapeutic potential for AD remains unclear. Here, we found that about 13.9% of Aβ42 and 8.9% of Aβ40 were removed from the blood when flowing through the liver, and this capacity was decreased with Aβ receptor LRP-1 expression down-regulated in hepatocytes in the aged animals. Partial blockage of hepatic blood flow increased Aβ levels in both blood and brain interstitial fluid. The chronic decline in hepatic Aβ clearance via LRP-1 knockdown specific in hepatocytes aggravated cerebral Aβ burden and cognitive deficits, while enhancing hepatic Aβ clearance via LRP-1 overexpression attenuated cerebral Aβ deposition and cognitive impairments in APP/PS1 mice. Our findings demonstrate that the liver physiologically clears blood Aβ and regulates brain Aβ levels, suggesting that a decline of hepatic Aβ clearance during aging could be involved in AD development, and hepatic Aβ clearance is a novel therapeutic approach for AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, this capacity decreases with age, which is partially attributed to the low expression of low-density lipoprotein receptor-related protein 1 (LRP-1) in hepatocytes.227–229”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [227]
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“Impairment of Aβ clearance is considered the main cause of sporadic AD, which accounts for 99% of all AD cases [29].”
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“Aging is considered the major risk factor for sporadic AD and leads to declined function in all organs of the whole body [13].”
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277 · cited 1×
“, are highly expressed in liver cells [15].”
Self-citationAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367 · cited 2×
“Phase III clinical trials with a peripheral injection of Aβ monoclonal antibodies aducanumab and lecanemab can substantially reduce brain PET Aβ signals in AD patients [3, 37].”
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Translating cell biology into therapeutic advances in Alzheimer's disease
Selkoe, D. J. (1999) · Nature · doi:10.1038/399a023 · Cited by 1,166 · cited 1×
“Therefore, understanding the mechanism of Aβ clearance from the brain could be crucial to establish interventions for AD [14, 28].”
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Self-citation
Research works printed but not linked: 1
- van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388:9–21. https://doi.org/10.1056/NEJMoa2212948 · DOI · Paper page
Cited by
Gut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 287
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Self-citationMetabolic Crosstalk between Liver and Brain: From Diseases to Mechanisms
Yang, X., Qiu, K., Jiang, Y., Huang, Y., Zhang, Y., & Liao, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147621 · Cited by 84
“%) from the bloodstream [26].”
BackgroundLamichhane, G., Liu, J., Lee, S., Lee, D., Zhang, G., & Kim, Y. (2024) · Nutrients · doi:10.3390/nu16020240 · Cited by 62
“The liver also plays a crucial role in the peripheral clearance of A β , influencing its increased efflux from the brain and reducing the A β load [12,13].”
BackgroundAssociation of microplastics in human cerebrospinal fluid with Alzheimer’s disease-related changes
He, P., Wang, F., Xi, G., Li, Y., Wang, F., Wang, H., Li, L., Ma, X., Han, Y., & Shi, Y. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.138748 · Cited by 64
Metadata
- Authors
- Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., Sun, P.-Y., Zeng, G.-H., Shen, Y.-Y., Shi, A.-Y., Jin, W.-S., Bu, X.-L., Liu, H.-M., Xu, Y.-M., Wang, J., & Wang, Y.-J.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Army Medical University (CN)
- Corresponding author
- Xu, Man-Yu
- Wang, Jun
- Wang, Yan-Jiang
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2023-03-25
- Volume
- 145
- Issue
- 6
- Pages
- 717-731
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W4360821293
- Cited by
- 110
- References
- 44
- Citations by year
- 2026: 34 · 2025: 32 · 2024: 33 · 2023: 11
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81930028, 31921003)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- amyloid-beta clearance, liver, Alzheimer's disease, LRP1, hepatocytes, hepatic blood flow, aging, amyloid-beta 42, Aβ40, APP/PS1 mice, cognitive impairment, therapeutic target
- MeSH terms
- Alzheimer Disease, Animals, Brain, Disease Models, Animal, Liver, Mice, Transgenic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease. https://app.cochat.ai/papers/10.1007/s00401-023-02559-z
- The paper
- Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., Sun, P.-Y., Zeng, G.-H., Shen, Y.-Y., Shi, A.-Y., Jin, W.-S., Bu, X.-L., Liu, H.-M., Xu, Y.-M., Wang, J., & Wang, Y.-J. (2023). Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease. Acta Neuropathologica. https://doi.org/10.1007/s00401-023-02559-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.